Follow
Richard B. Schwab
Richard B. Schwab
Senior Medical Director, Genentech
Verified email at gene.com
Title
Cited by
Cited by
Year
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
5782016
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively …
R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ...
JAMA oncology 6 (5), 676-684, 2020
5182020
Reproductive risk factors and breast cancer subtypes: a review of the literature
KN Anderson, RB Schwab, ME Martinez
Breast cancer research and treatment 144, 1-10, 2014
4772014
Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ...
New England Journal of Medicine 375 (1), 11-22, 2016
3582016
HER2 aberrations in cancer: implications for therapy
M Yan, BA Parker, R Schwab, R Kurzrock
Cancer treatment reviews 40 (6), 770-780, 2014
2542014
A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1: the caveolin scaffolding domain is both necessary and sufficient for membrane …
A Schlegel, RB Schwab, PE Scherer, MP Lisanti
Journal of Biological Chemistry 274 (32), 22660-22667, 1999
1961999
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
S Kato, KH Kim, HJ Lim, A Boichard, M Nikanjam, E Weihe, DJ Kuo, ...
Nature communications 11 (1), 4965, 2020
1942020
Exploring the landscape of focal amplifications in cancer using AmpliconArchitect
V Deshpande, J Luebeck, NPD Nguyen, M Bakhtiari, KM Turner, ...
Nature communications 10 (1), 392, 2019
1912019
Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
S Zhang, B Cui, H Lai, G Liu, EM Ghia, GF Widhopf, Z Zhang, CCN Wu, ...
Proceedings of the National Academy of Sciences 111 (48), 17266-17271, 2014
1902014
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ...
The Lancet Oncology 23 (1), 149-160, 2022
1872022
Molecular tumor board: the University of California San Diego Moores cancer center experience
M Schwaederle, BA Parker, RB Schwab, PT Fanta, SG Boles, GA Daniels, ...
The oncologist 19 (6), 631-636, 2014
1862014
Gene-target recognition among members of the myc superfamily and implications for oncogenesis
RC O'Hagan, N Schreiber-Agus, K Chen, G David, JA Engelman, ...
Nature genetics 24 (2), 113-119, 2000
1752000
Precision oncology: The UC San Diego moores cancer center predict experience
M Schwaederle, BA Parker, RB Schwab, GA Daniels, DE Piccioni, ...
Molecular cancer therapeutics 15 (4), 743-752, 2016
1682016
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
M Schwaederle, H Husain, PT Fanta, DE Piccioni, S Kesari, RB Schwab, ...
Oncotarget 7 (9), 9707, 2016
1602016
Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia
RP Wu, T Hayashi, HB Cottam, G Jin, S Yao, CCN Wu, MD Rosenbach, ...
Proceedings of the National Academy of Sciences 107 (16), 7479-7484, 2010
1552010
Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia
RP Wu, T Hayashi, HB Cottam, G Jin, S Yao, CCN Wu, MD Rosenbach, ...
Proceedings of the National Academy of Sciences 107 (16), 7479-7484, 2010
1552010
Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer
V Padler-Karavani, N Hurtado-Ziola, M Pu, H Yu, S Huang, S Muthana, ...
Cancer research 71 (9), 3352-3363, 2011
1502011
Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis
BT Mausbach, RB Schwab, SA Irwin
Breast cancer research and treatment 152, 239-246, 2015
1462015
Use of liquid biopsies in clinical oncology: pilot experience in 168 patients
M Schwaederle, H Husain, PT Fanta, DE Piccioni, S Kesari, RB Schwab, ...
Clinical cancer research 22 (22), 5497-5505, 2016
1432016
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
L Pusztai, C Yau, DM Wolf, HS Han, L Du, AM Wallace, E String-Reasor, ...
Cancer cell 39 (7), 989-998. e5, 2021
1422021
The system can't perform the operation now. Try again later.
Articles 1–20